Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
May 1, 2018
RegMed Investors’ (RMi) closing bell; hanging with a different crowd
April 30, 2018
RegMed Investors’ (RMi) closing bell; finally April is over
April 28, 2018
RegMed Investors’ (RMi) closing bell; enough of being oversold
April 26, 2018
RegMed Investors’ (RMi) closing bell; a rally finish
April 25, 2018
RegMed Investors’ (RMi) closing bell; equities flip, flop while playing catch-up
April 25, 2018
RegMed Investors’ (RMi) pre-open: a game of pick-up-stocks with winds blowing
April 24, 2018
RegMed Investors’ (RMi) closing bell; an embattled sector
April 16, 2018
RegMed Investors’ (RMi) closing bell; losses chain the sector together
April 11, 2018
RegMed Investors’ (RMi) closing bell; sector pricing withers
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cytori (CYTX) – Started the year seeking "strategic alternatives" with a share priced at $0.29, seeing a couple of highs of $0.47 with a 2/1 value of $0.40 which has been dropping and currently (2/16) at $0.32. A sory of missed oppurtunity thrown at the feet of its CEO ... incremental development news are minimal ... it's all about whether the FDA requests ... MORE data and trial.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors